DEMG Stock Overview
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.015|
|52 Week High||UK£0.023|
|52 Week Low||UK£0.01|
|1 Month Change||-1.61%|
|3 Month Change||-12.86%|
|1 Year Change||15.09%|
|3 Year Change||41.86%|
|5 Year Change||-57.93%|
|Change since IPO||-94.83%|
Recent News & Updates
Deltex Medical Group (LON:DEMG) Is Making Moderate Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Does Deltex Medical Group (LON:DEMG) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|DEMG||GB Medical Equipment||GB Market|
Return vs Industry: DEMG exceeded the UK Medical Equipment industry which returned -8.7% over the past year.
Return vs Market: DEMG exceeded the UK Market which returned 13.8% over the past year.
|DEMG Average Weekly Movement||5.1%|
|Medical Equipment Industry Average Movement||5.1%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.8%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: DEMG is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DEMG's weekly volatility (5%) has been stable over the past year.
About the Company
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient’s central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting.
Deltex Medical Group Fundamentals Summary
|DEMG fundamental statistics|
Is DEMG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DEMG income statement (TTM)|
|Cost of Revenue||UK£737.00k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0013|
|Net Profit Margin||-31.78%|
How did DEMG perform over the long term?See historical performance and comparison
Is Deltex Medical Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DEMG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DEMG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DEMG is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.
PE vs Market: DEMG is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DEMG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DEMG is overvalued based on its PB Ratio (3.9x) compared to the GB Medical Equipment industry average (3.5x).
How is Deltex Medical Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if DEMG's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if DEMG's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DEMG's revenue (19.5% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: DEMG's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DEMG's Return on Equity is forecast to be high in 3 years time
How has Deltex Medical Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DEMG is currently unprofitable.
Growing Profit Margin: DEMG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DEMG is unprofitable, but has reduced losses over the past 5 years at a rate of 37.2% per year.
Accelerating Growth: Unable to compare DEMG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DEMG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (97.5%).
Return on Equity
High ROE: DEMG has a negative Return on Equity (-34.19%), as it is currently unprofitable.
How is Deltex Medical Group's financial position?
Financial Position Analysis
Short Term Liabilities: DEMG's short term assets (£2.0M) exceed its short term liabilities (£1.7M).
Long Term Liabilities: DEMG's short term assets (£2.0M) exceed its long term liabilities (£1.3M).
Debt to Equity History and Analysis
Debt Level: DEMG's net debt to equity ratio (28.8%) is considered satisfactory.
Reducing Debt: DEMG's debt to equity ratio has reduced from 61.5% to 54.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DEMG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: DEMG has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 39.7% each year.
What is Deltex Medical Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DEMG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DEMG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DEMG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DEMG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DEMG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andy Mears (52 yo)
Mr. Andrew Jonathan Mears, also known as Andy, has been Chief Executive Officer and Director of Deltex Medical Group plc since June 13, 2018. Mr. Mears was Managing Director of Deltex Medical Group plc sin...
CEO Compensation Analysis
Compensation vs Market: Andy's total compensation ($USD290.25K) is about average for companies of similar size in the UK market ($USD324.53K).
Compensation vs Earnings: Andy's compensation has increased whilst the company is unprofitable.
Experienced Management: DEMG's management team is considered experienced (3.4 years average tenure).
Experienced Board: DEMG's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.
Deltex Medical Group plc's employee growth, exchange listings and data sources
- Name: Deltex Medical Group plc
- Ticker: DEMG
- Exchange: AIM
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£8.920m
- Shares outstanding: 584.94m
- Website: https://www.deltexmedical.com
Number of Employees
- Deltex Medical Group plc
- Terminus Road
- West Sussex
- West Sussex
- PO19 8TX
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/30 21:33|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.